FindTrial
Sign In

Study on Chemotherapy Treatment for Pancreatic Cancer from Cyst Growths Intraductal Papillary Mucinous Neoplasms (IPMN)

Multicenter Retrospective Analysis of Adjuvant Chemotherapy Regimen in IPMN derived PDAC - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/076077
Enrollment
1000
Registered
2024-10-30
Start date
Unknown
Completion date
Unknown
Last updated
2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D136- Benign neoplasm of pancreas

Interventions

Intervention1: Not applicable: Not Applicable Control Intervention1: Not applicable: Not applicable

Sponsors

NYU Grossman School Of Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: -Patients with resected IPMN derived PDAC from 2005 to 2022

Exclusion criteria

Exclusion criteria: -Patients below 18 years of age -Patients with concomitant PDAC, metastatic disease at time of resection, Neoadjuvant therapy or 90 day mortality

Design outcomes

Primary

MeasureTime frame
whether an adjuvant chemotherapy regimen (monotherapy gemcitabine vs. combination gemcitabine vs. FOLFIRINOX) is associated with overall survival in patients with respected IPMN-derived PDAC.Timepoint: Overall survival will be calculated as the time between date of the surgery to the date of the last known follow-up visit or death 5 years—

Secondary

MeasureTime frame
Recurrence free survivalTimepoint: Recurrence free survival will be calculated from the date of surgery to the date of documented cancer recurrence or death, whichever comes first—

Countries

China, Germany, India, Italy, Netherlands, Republic of Korea, Switzerland, United States of America

Contacts

Public ContactDr Shailesh Shrikhande

TATA MEMORIAL HOSPITAL

shailushrikhande@hotmail.com9820224761

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026